Viking Global Investors

AssetWatch specializes in proactive predictive maintenance solutions. It offers a rapidly deployable remote condition monitoring service featuring wireless sensors, communication hubs, advanced software, and expert analysis. The company combines predictive analytics with expert insights to provide actionable recommendations, helping global manufacturers minimize unplanned downtime and transition from reactive to proactive maintenance.

Canopy Tax Inc. is a software company that specializes in providing tax resolution and practice management solutions for accountants and tax professionals. Founded in 2014 and based in Lehi, Utah, the company offers a cloud-based platform that enhances workflow management by integrating tools for client management, document management, invoicing, payment, and project management. Designed to streamline processes and reduce administrative tasks, Canopy's software enables accounting professionals to improve efficiency and enhance the client experience by consolidating essential functions into a single, user-friendly interface. The platform serves thousands of accounting practitioners across the country, helping them to organize their teams and optimize their operations.

Neurona Therapeutics is a biotechnology company developing cell-based therapies for treating neurological disorders. Founded by neuroscientists at UCSF in 2008, the company focuses on generating therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system.

Valsoft Corporation is a holding company that focuses on acquiring and growing vertical-market software enterprises. The company aims to provide software and related technology services to a diverse and expanding consumer base. Valsoft employs a decentralized management approach, allowing its acquired companies to operate independently while benefiting from shared resources, analytics, guidance, and capital. This strategy enables these companies to achieve stability and enhance their marketing efforts, ultimately fostering growth and innovation in the software industry.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Humaneva Group specializes in clinical research services, facilitating efficient data exchange between patients, investigators, research centers, and data standards. The company employs technology and data-driven strategies to prioritize patient care and conduct high-quality research, ultimately aiding in the development of new treatments for the pharmaceutical industry.

GondolaBio is a biopharmaceutical company dedicated to researching, developing, and manufacturing pharmaceutical products. Its primary focus is on creating therapeutics for patients with genetic diseases, addressing high unmet medical needs across various therapeutic areas and stages of development. The company leverages biological research to drive its mission, aiming to enable the healthcare industry to effectively treat and manage rare genetic conditions.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

Antheia is a biotechnology company focused on harnessing the medicinal power of nature through innovative manufacturing processes. The company employs synthetic biology to overcome traditional drug manufacturing limitations by reconstructing complex molecules in yeast, eliminating the need for medicinal plants. This approach ensures reliable, consistent, and widespread availability of essential medicines. Antheia's methods transform the pharmaceutical supply chain, offering cost-competitive, plant-based medicines that provide healthcare organizations with natural and healthier medication options.

Clip is transforming card acceptance in Mexico by providing portable card-reading hardware and a digital payment platform that enables businesses to accept all credit and debit cards, including contactless payments. The company's solutions allow businesses to turn smartphones or tablets into card terminals, facilitating seamless transactions without the need for complicated paperwork or monthly fees. By focusing on empowering Mexican businesses, Clip helps them increase sales and grow by offering a user-friendly application that simplifies payment acceptance. This approach positions Clip as a vital ally for merchants seeking efficient and accessible payment solutions.

AlphaSense is a market intelligence platform that helps research and business professionals discover, navigate, and monitor financial data and disclosures. The web-based platform collects data from filings, research, news, and other sources and makes it searchable through artificial intelligence and natural language processing, enabling users to search, set alerts, and analyze data points with accuracy. It serves a large enterprise base, including financial institutions and a majority of S&P 500 clients. Headquartered in New York, the company also operates offices in London, Helsinki, and Pune.

Diagonal Therapeutics is a biotechnology startup focused on discovering and developing agonist antibodies. The company utilizes a unique platform that integrates proprietary computational and experimental methodologies to address longstanding challenges in agonist antibody drug development. By overcoming these obstacles, Diagonal Therapeutics aims to enable medical practitioners to deliver therapies for conditions such as hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension, thereby advancing treatment options for patients.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Neurona Therapeutics is a biotechnology company developing cell-based therapies for treating neurological disorders. Founded by neuroscientists at UCSF in 2008, the company focuses on generating therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system.

Valsoft Corporation is a holding company that focuses on acquiring and growing vertical-market software enterprises. The company aims to provide software and related technology services to a diverse and expanding consumer base. Valsoft employs a decentralized management approach, allowing its acquired companies to operate independently while benefiting from shared resources, analytics, guidance, and capital. This strategy enables these companies to achieve stability and enhance their marketing efforts, ultimately fostering growth and innovation in the software industry.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

Founded in 2017 and based in Boston, Lightmatter is an artificial intelligence hardware company that specializes in integrated optical technology. It designs photonic chips to enable data processing and communication through light signals, aiming to improve efficiency and scalability for AI data centers.

Keboola is a Prague-based company founded in 2007 by Mirek Burkon, Milan Veverka, and Petr Simecek. It specializes in providing a cloud-based data preparation platform that assists clients in capturing, analyzing, and utilizing crucial information for their internal analytics projects and data products. Keboola's software suite simplifies data analysis in areas such as churn prediction, logistics flow, and revenue prediction, offering businesses quick access to vital insights.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Founded in 2017, DermBiont is a biotechnology company based in Boston, Massachusetts. It specializes in developing skin microbiome therapeutics to treat and prevent various skin diseases, with a focus on fungal infections.

AlphaSense is a market intelligence platform that helps research and business professionals discover, navigate, and monitor financial data and disclosures. The web-based platform collects data from filings, research, news, and other sources and makes it searchable through artificial intelligence and natural language processing, enabling users to search, set alerts, and analyze data points with accuracy. It serves a large enterprise base, including financial institutions and a majority of S&P 500 clients. Headquartered in New York, the company also operates offices in London, Helsinki, and Pune.

Inhibrx, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, that specializes in developing a diverse pipeline of novel biologic therapeutic candidates. The company's focus areas include oncology, orphan diseases, and infectious diseases, employing advanced protein engineering techniques, including its proprietary sdAb platform. Among its leading candidates is INBRX-109, a multivalent agonist of death receptor 5, currently in Phase 1 trials for treating solid tumors, including sarcomas. Another candidate, INBRX-105, serves as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB, also in Phase 1 trials for PD-L1 expressing tumors. Additional candidates include INBRX-101, aimed at alpha-1 antitrypsin deficiency, and INBRX-103, targeting cluster of differentiation 47. The company's preclinical programs encompass innovative therapies such as INBRX-106, a hexavalent agonist of OX40, and INBRX-111, a multifunctional antibody targeting Pseudomonas aeruginosa. Founded in 2010, Inhibrx has established collaborations with prominent organizations and received funding from various granting agencies.

Allonnia LLC is a biotechnology company based in Boston, Massachusetts, founded in 2019, that specializes in waste remediation services. The company focuses on developing enzymes, proteins, and microbes that effectively degrade or metabolize environmental contaminants, facilitating the recovery and upcycling of valuable materials from waste. Allonnia aims to provide innovative solutions to pressing environmental challenges, including safer water and cleaner mining, while promoting sustainability. Their unique approach integrates biology with advanced technology to create systems that transform waste into useful resources. Allonnia's commitment to environmental stewardship and innovation has garnered industry recognition, positioning it as a leader in the field of biotechnology and waste management.

Ecovative Design LLC, established in 2007, is a biomaterials company based in Green Island, New York, with manufacturing facilities in Troy and Paradise, California. The company specializes in developing and producing sustainable materials derived from mushroom roots, known as mycelium. Ecovative's product portfolio includes Myco board, used for furniture components and work surfaces; Myco foam, employed in packaging, insulation, and acoustics; and Myco make, used in toys and other consumer goods. The company's innovative process, inspired by the natural bonding of wood chips by mycelium, aims to replace conventional plastics and foams with eco-friendly alternatives. Ecovative's products perform comparably to existing synthetics while offering a lower environmental impact. The company has received numerous awards and grants, including support from the American Society of Mechanical Engineers, the National Collegiate Inventors and Innovators Alliance, the New York State Energy Research and Development Authority, and the Environmental Protection Agency, enabling its growth and continued innovation in sustainable materials.

Founded in 2017 and based in Boston, Lightmatter is an artificial intelligence hardware company that specializes in integrated optical technology. It designs photonic chips to enable data processing and communication through light signals, aiming to improve efficiency and scalability for AI data centers.

Solarea Bio is a biotechnology company that develops microbial therapeutics derived from healthy food sources. It uses computational approaches to create synergistic combinations of bacteria, fungi, and prebiotic fibers with anti-inflammatory properties, targeting chronic health conditions such as osteopenia and osteoporosis in postmenopausal women.

Abdera is an oncology company developing targeted alpha therapies for patients with relapsed, refractory, or metastatic cancers. Its precision oncology platform integrates drug development and antibody engineering technologies to create novel radiopharmaceuticals that specifically target tumors while minimizing systemic toxicities.

AlphaSense is a market intelligence platform that helps research and business professionals discover, navigate, and monitor financial data and disclosures. The web-based platform collects data from filings, research, news, and other sources and makes it searchable through artificial intelligence and natural language processing, enabling users to search, set alerts, and analyze data points with accuracy. It serves a large enterprise base, including financial institutions and a majority of S&P 500 clients. Headquartered in New York, the company also operates offices in London, Helsinki, and Pune.

ID.me provides secure identity verification solutions for individuals and businesses across various sectors. It offers services such as identity proofing, authentication, multi-factor authentication, document verification, compliance monitoring, and group affiliation verification. ID.me's platform enables users to prove their identity securely online, access benefits and services, and avail discounts.

Pragma Bio is a biotechnology company that uses microbiome-based approaches to discover therapies for cancer and autoimmune diseases, combining genomic sequencing, artificial intelligence, and synthetic biology to identify biomarkers and develop therapeutics through a data-driven platform that aggregates public and private data to build a microbiome database and reveal connections across microbial and clinical data. The company pursues small-molecule discovery from human-associated bacteria, focusing on the gut-immune axis, and aims to deliver health-indicative molecules with robust safety profiles, while the platform supports risk stratification and outcome prediction for patients by leveraging real-world data. Pragma Bio was founded in 2018 in Millbrae, California by Peter McCaffrey, Kovi Bessoff, Ayin Vala and Kareem Barghouti.

SetPoint Medical Corporation is a clinical-stage medical device company developing implantable neuromodulation therapies to treat chronic inflammatory and autoimmune diseases. Its platform uses vagus nerve stimulation to activate the body's inflammatory reflex, aiming to produce a systemic immune-restorative effect and offer an alternative to drug therapy for conditions such as rheumatoid arthritis and inflammatory bowel disease. Based in Valencia, California.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Mantra Bio, Inc. is a biotechnology company focused on developing targeted therapeutics through its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). Founded in 2016 and based in San Francisco, California, the company utilizes its REVEAL platform, which integrates computational biology, wet lab techniques, and automation. This innovative approach leverages the diversity of exosomes to design and optimize therapeutics aimed at various tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process to ensure the reproducibility and high purity of its next-generation therapeutics, enabling medical practitioners to address challenging diseases effectively.

Pearl Health is a healthcare technology company founded in 2020 that focuses on empowering primary care providers and organizations to enhance patient care and optimize financial performance within value-based care models. The company offers a care-delivery and billing platform that simplifies administrative burdens for physicians, allowing them to concentrate on patient care. Pearl Health provides a fixed per-member-per-month payment structure for traditional members, along with clinical insights through analytics and performance optimization services. By partnering with thousands of primary care providers across 44 states, Pearl aims to improve healthcare quality, lower overall costs, and reward providers for keeping patients healthy. The company's team comprises physicians, public health experts, technologists, and risk management professionals who are committed to addressing significant challenges in the healthcare system.

Vector Biomed is a cutting-edge company specializing in the design and Good Manufacturing Practice (GMP) manufacturing of custom lentiviral vectors. These vectors are essential for the production of gene therapies, including CAR-T cell therapies and stem cell gene therapies. The company provides high-titer, algorithm-optimized lentiviral vectors using a serum-free, chemically-defined process, facilitating a swift transition from therapeutic concept to clinical development. By ensuring the reliability and quality of its vector production, Vector Biomed supports drug developers in efficiently advancing vector-based medicines toward clinical trials and commercialization.

Arctic Wolf Networks offers cloud-native security operations technology, providing Managed Detection and Response, Managed Risk, and Managed Cloud Monitoring services. Its team of concierge security engineers acts as an extension of clients' internal teams, offering tailored threat detection, response, and ongoing risk management to protect valuable business data.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

AlphaSense is a market intelligence platform that helps research and business professionals discover, navigate, and monitor financial data and disclosures. The web-based platform collects data from filings, research, news, and other sources and makes it searchable through artificial intelligence and natural language processing, enabling users to search, set alerts, and analyze data points with accuracy. It serves a large enterprise base, including financial institutions and a majority of S&P 500 clients. Headquartered in New York, the company also operates offices in London, Helsinki, and Pune.

Locus Biosciences is a biotechnology company focused on developing a CRISPR-engineered precision antibacterial platform aimed at transforming the treatment of bacterial diseases. The company integrates the antibacterial capabilities of CRISPR-Cas3 technology with the effective and safe delivery of bacteriophages, which are viruses that specifically target bacteria. This innovative approach allows for rapid initiation of treatment by physicians, leading to improved medical outcomes for patients. Through its advanced platform, Locus Biosciences seeks to address the challenges posed by pathogenic bacteria in a precise and targeted manner.

Conductor Tecnologia S.A. is a prominent payments processor and banking-as-a-service provider based in São Paulo, Brazil. Founded in 1997, the company specializes in credit card and electronic payment processing, along with collection and billing services for third parties. Leveraging its proprietary API-based digital processing platform, Conductor serves nearly 250 corporate clients across various industries, processing over $20 billion annually. The company manages approximately 29 million active and 80 million total end customer payment accounts, facilitating transactions at more than 2.5 million points of sale throughout Latin America. Its comprehensive suite of services empowers clients to offer efficient payment solutions to their customers.

Revenova TMS is a cloud-based transportation management system designed for shippers, brokers, and third-party logistics (3PL) companies. The platform facilitates the complete shipment life-cycle, enabling users to plan, price, optimize, tender, schedule, track, manage freight, settle invoices, and handle claims across various transportation modes, including truck, rail, air, and ocean. By fostering effective communication and collaboration among customers, carriers, and team members, Revenova TMS streamlines the process of managing shipments. The software enhances operational efficiency and intelligence, helping clients improve their freight movement processes while managing critical relationships and documentation.

BiomEdit discovers, designs, and develops novel probiotics and microbiome-derived bioactives using a unique platform that combines high-throughput sequencing and data analytics. Their products aim to promote animal health without antibiotics, addressing unmet needs in animal agriculture and food security.

Valsoft Corporation is a holding company that focuses on acquiring and growing vertical-market software enterprises. The company aims to provide software and related technology services to a diverse and expanding consumer base. Valsoft employs a decentralized management approach, allowing its acquired companies to operate independently while benefiting from shared resources, analytics, guidance, and capital. This strategy enables these companies to achieve stability and enhance their marketing efforts, ultimately fostering growth and innovation in the software industry.

Cazoo Limited is an online marketplace that revolutionizes the car buying experience for consumers in the UK and Europe. Founded in 2018 and headquartered in London, Cazoo offers a platform where customers can buy, finance, or rent used cars entirely online. The service allows users to select their desired vehicle and have it delivered to their doorstep within hours, making the process efficient and convenient. By streamlining car purchases and rentals, Cazoo aims to simplify the traditionally complex experience of buying a car.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

Cognism, established in 2015, is a London-based SaaS company specializing in end-to-end sales acceleration. It leverages patented AI technology to provide B2B sales teams with real-time, high-quality data, including company, people, and event information. Cognism's platform integrates seamlessly with major CRM and email systems, helping sales teams efficiently prospect, manage their database, and grow revenue. The company, with offices in the US, Macedonia, and Croatia, focuses on enriching CRM records, identifying customer trends, and streamlining lead generation.

Founded in 2017, DermBiont is a biotechnology company based in Boston, Massachusetts. It specializes in developing skin microbiome therapeutics to treat and prevent various skin diseases, with a focus on fungal infections.

Mythic Therapeutics is a biotechnology company specializing in innovative cancer therapeutics. It focuses on enhancing antibody-drug conjugates (ADCs) and other antibody-based therapies using advanced protein engineering techniques, aiming to boost potency without compromising safety.

Color is a healthcare technology company that offers a comprehensive platform for population health management, facilitating equitable and accessible healthcare delivery. The company specializes in large-scale health initiatives, providing solutions that include population genomics programs and high-throughput testing services, such as those for COVID-19. By centralizing essential healthcare capabilities, Color enables businesses, schools, and state public health departments to implement effective preventive health programs, regardless of the geographical distribution of their populations. Its innovative approach addresses various healthcare logistics challenges, streamlining processes related to testing, screening, treatment, and referrals, while creating diverse market opportunities and revenue streams for clinical teams.

Cloudbeds is a hospitality management software developer headquartered in San Diego, California, founded in 2012. The company offers an integrated, cloud-based platform designed to simplify operations for independent hoteliers and hosts. Its all-in-one hotel management system provides real-time, two-way integration with various distribution channels, alongside property, payment, and revenue management services. By empowering clients in the hospitality industry with advanced technology, Cloudbeds enables them to enhance revenue, streamline operations, and improve guest experiences.

Arcaea is a biotechnology company dedicated to transforming the beauty and personal care industry by leveraging biology as a creative tool for self-expression. The company aims to develop innovative ingredients and product experiences through advanced technologies such as DNA sequencing, biological engineering, and fermentation. By focusing on the potential of biology, Arcaea seeks to create sustainable and eco-friendly ingredients, thereby offering the beauty industry new options that minimize environmental impact. Through its pioneering approach, Arcaea aspires to redefine the future of beauty by unlocking previously unattainable product capabilities.

Patina is a healthcare company reinventing primary care for older adults by delivering a human, personalized, on-demand care model designed to improve the healthcare and aging experience for seniors and their families. The approach centers on the specific needs and values of aging individuals, offering flexible access to care and enabling families and loved ones to participate as part of the care team. By focusing on dignity in aging and a coordinated, person-centered experience, Patina aims to align medical care with daily living and the goals of aging adults.

Groove Labs, Inc. is a sales engagement platform that specializes in automating non-sales activities to enhance the productivity of sales teams. Founded in 2014 and headquartered in San Francisco, with additional offices in San Diego and Bellevue, the company offers a range of solutions, including email and calendar integration, custom multi-step campaign creation, and a dialer tool designed to streamline the sales process. Groove's Salesforce-native architecture allows for accurate reporting and compliance with global privacy laws, making it suitable for enterprises. Its platform is utilized by over 50,000 sales representatives and customer success managers at major companies, helping them reclaim valuable time for relationship-building and revenue generation. Groove has consistently received high customer satisfaction ratings and has been recognized as one of the fastest-growing privately held companies in the United States.

Global Processing Services Limited is a payments processor that specializes in managing credit, debit, and prepaid card transactions on a global scale. Founded in 2007 and headquartered in Douglas, Isle of Man, the company has developed the GPS Apex platform, which serves as an integrated global processing solution. This proprietary technology facilitates secure and reliable transaction processing while enabling fintech companies to innovate within the payments industry. The GPS Apex platform integrates with various stakeholders, including clients, issuers, program managers, and card manufacturers, thereby enhancing the overall efficiency and effectiveness of payment processing.

Roivant Sciences is a biopharmaceutical company dedicated to advancing the development of innovative late-stage drug candidates and enhancing healthcare delivery. The company aims to expedite the process of bringing new medicines to patients while reducing associated costs, thereby benefiting the healthcare system. Roivant achieves this by creating specialized entities known as "Vants," which are agile biotech and healthcare technology companies that leverage unique talent sourcing and incentive alignment strategies. In addition to its focus on biopharmaceuticals, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its commercial-stage drug candidates is VTAMA, a treatment for plaque psoriasis in adults, along with several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, which are at various stages of development.

AlphaSense is a market intelligence platform that helps research and business professionals discover, navigate, and monitor financial data and disclosures. The web-based platform collects data from filings, research, news, and other sources and makes it searchable through artificial intelligence and natural language processing, enabling users to search, set alerts, and analyze data points with accuracy. It serves a large enterprise base, including financial institutions and a majority of S&P 500 clients. Headquartered in New York, the company also operates offices in London, Helsinki, and Pune.

Astarte Medical Partners, Inc. is a clinical intelligence company focused on enhancing health outcomes for children with medical complexities, particularly in neonatal intensive care units (NICUs). Incorporated in 2016 and based in Yardley, Pennsylvania, the company develops software that delivers a comprehensive view of clinical data in real time, specifically aimed at assessing the gut health of preterm infants. This platform allows clinical care teams to standardize and optimize feeding practices and protocol-driven care, thereby facilitating informed decision-making. Astarte Medical's suite of digital tools and predictive analytics supports nutrition and feeding practices, enabling healthcare providers to monitor growth and track clinical outcomes effectively. By improving care practices in acute settings, the company strives to make a significant impact on the long-term health of vulnerable pediatric populations.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012, specializing in innovative technologies for cancer research and immunotherapy. The company has developed proprietary systems that capture, grow, and analyze cancer cells directly from patient blood samples, allowing for precise control over primary cell phenotype and function. This technology enhances the development and production of cell therapies, providing scientists with advanced tools for cell maintenance, expansion, and optimization. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to improve predictive therapy development and clinical outcomes for patients undergoing immunotherapy.

Biome Makers Inc. is a biotechnology company based in San Francisco, California, specializing in the identification and understanding of microbiomes, particularly in agricultural contexts. Founded in 2015, the company employs advanced DNA sequencing technologies and proprietary Intelligent Computing systems to deliver detailed, crop-specific insights and recommendations. This innovative approach enables growers and manufacturers to analyze soil ecosystems effectively, enhancing agricultural production and product quality through data-driven insights. By simplifying complex microbiome data, Biome Makers supports its customers in optimizing their agricultural practices and improving overall outcomes.

Algen Biotechnologies, Inc. is a therapeutic discovery company focused on drug development through an innovative platform that decodes functional gene networks. The company leverages advanced technologies, including CRISPR and machine learning, to uncover disease-driving RNA messages. By analyzing complex disease signaling and gene networks, Algen aims to facilitate drug discovery for cancer and other diseases with significant unmet medical needs. Its approach seeks to provide valuable insights for drug companies, enabling them to identify and develop effective treatments.

Apeel Sciences, based in California, addresses the global food waste crisis by developing plant-derived solutions that extend the shelf life of fresh produce. Founded in 2012, the company creates pre-and post-harvest products using natural plant extracts, such as Edipeel and Invisipeel, which protect fruits and vegetables from environmental factors and pre-harvest issues. These innovations effectively double the lifespan of harvested crops without refrigeration, helping to reduce spoilage and conserve resources like water and energy. By leveraging materials found in the skins, peels, and seeds of fruits and vegetables, Apeel aims to minimize food waste and promote sustainability throughout the supply chain. The company's efforts are supported by a range of private investors and philanthropic organizations.

Talkdesk Inc., founded in 2011 by Cristina Fonseca and Tiago Paiva, specializes in browser-based cloud contact center software for small businesses. Headquartered in San Francisco with offices across Europe and North America, Talkdesk offers an end-to-end solution that optimizes customer engagement, workforce management, and analytics. Its platform enables users to identify callers before answering, provides comprehensive customer insights from various sources, monitors call performance in real-time, and offers intelligent customer self-service data for agents. With over 1,400 enterprise clients worldwide, including IBM and Acxiom, Talkdesk helps businesses enhance customer satisfaction, productivity, and cost savings through its adaptable platform.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Zentera Therapeutics is a biopharmaceutical company.

Genomatica, Inc. is a biotechnology company based in San Diego, California, specializing in the development of manufacturing processes for intermediate and basic chemicals derived from renewable feedstocks. Founded in 1998, the company utilizes its proprietary biotechnology platform to create fermentation-based processes and to engineer microorganisms that facilitate the conversion of these feedstocks into essential chemicals. Genomatica has successfully commercialized processes for chemicals such as butanediol, which is used in biodegradable plastics and apparel, and butylene glycol, commonly found in cosmetics and personal care products. The company is also actively working on bio-nylon and has developed a pipeline targeting the production of 20 different chemicals. Recognized for its innovative technologies, Genomatica has received numerous accolades, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Arctic Wolf Networks offers cloud-native security operations technology, providing Managed Detection and Response, Managed Risk, and Managed Cloud Monitoring services. Its team of concierge security engineers acts as an extension of clients' internal teams, offering tailored threat detection, response, and ongoing risk management to protect valuable business data.

PROCEPT BioRobotics is a medical device company specializing in urology. It develops and sells robotic systems for minimally invasive urologic surgery, with a focus on treating benign prostatic hyperplasia (BPH). Its flagship product, the AquaBeam Robotic System, uses image-guided technology to deliver effective and durable outcomes independent of prostate size or surgeon experience.

Antheia is a biotechnology company focused on harnessing the medicinal power of nature through innovative manufacturing processes. The company employs synthetic biology to overcome traditional drug manufacturing limitations by reconstructing complex molecules in yeast, eliminating the need for medicinal plants. This approach ensures reliable, consistent, and widespread availability of essential medicines. Antheia's methods transform the pharmaceutical supply chain, offering cost-competitive, plant-based medicines that provide healthcare organizations with natural and healthier medication options.

Iterable, Inc. is a consumer growth marketing and user engagement platform based in San Francisco, California, founded in 2013. It caters primarily to mid-market and enterprise B2C companies across various sectors, including e-commerce, media, financial services, and political campaigns. The platform enables marketers to engage users through multiple channels such as email, mobile, social media, and the web, providing features like real-time segmentation, automation, customization, and A/B testing. Additionally, Iterable's solutions support engineers in triggering campaigns, exporting metrics, and managing workflows. By harnessing artificial intelligence and behavior-driven data, Iterable helps organizations create individualized communications that enhance customer interactions and drive growth throughout the customer lifecycle.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Motif FoodWorks, Inc. is a bio-organism engineering company based in Boston, Massachusetts, that specializes in developing innovative food ingredients. The company focuses on producing animal-free proteins, including meat alternatives and dairy-free proteins, catering to the growing demand for plant-based food solutions. By utilizing fermentation technology, Motif creates essential proteins and nutrients that enhance both nutrition and flavor in food products. The company collaborates with chefs, health experts, and food innovators to develop new ingredient solutions aimed at transforming the food industry and promoting sustainability. Established in 2018 and originally known as Motif Ingredients, Motif FoodWorks rebranded in 2019 to reflect its commitment to advancing the next generation of healthy and plant-based foods.

Clip is transforming card acceptance in Mexico by providing portable card-reading hardware and a digital payment platform that enables businesses to accept all credit and debit cards, including contactless payments. The company's solutions allow businesses to turn smartphones or tablets into card terminals, facilitating seamless transactions without the need for complicated paperwork or monthly fees. By focusing on empowering Mexican businesses, Clip helps them increase sales and grow by offering a user-friendly application that simplifies payment acceptance. This approach positions Clip as a vital ally for merchants seeking efficient and accessible payment solutions.

Nuvalent is a clinical stage biotechnology company specializing in the development of targeted therapies aimed at clinically validated kinase targets in cancer. Focusing on small molecules, Nuvalent employs a structure-based design approach to create treatments that possess high selectivity, intending to address the limitations of existing therapies by overcoming resistance and minimizing side effects. The company is advancing a promising pipeline that includes lead programs targeting ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). Additionally, Nuvalent is engaged in various discovery-stage research initiatives that aim to expand its therapeutic offerings.

Druva offers cloud-based data protection and management solutions. Its platform, built on AWS, provides globally accessible, scalable, and autonomous enterprise data resiliency. Customers can reduce costs by up to 50% by eliminating hardware expenses and capacity planning. Druva's platform transforms backup data into an asset, enhancing governance, cyber resiliency, and decision-making.

Atlast Food Co. is a food technology company based in Green Island, New York, specializing in the development of structural ingredients for plant-based and whole cut meat products. Established in 2020, Atlast aims to create delicious, environmentally sustainable foods that are rooted in nature. The company's product line includes innovative offerings such as plant-based bacon and steaks, reflecting its commitment to transforming the meat alternative market with high-quality, whole cut options.

1Health is a platform that hosts production systems and data. They offer designed to help them maintain this data integrity and stay compliant with HIPAA, GDPR, and all related health information regulations. They provide a modern, secure, and user-friendly software platform that allows diagnostic testing results to be accurately delivered in minutes.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Founded in 2017 and based in Boston, Lightmatter is an artificial intelligence hardware company that specializes in integrated optical technology. It designs photonic chips to enable data processing and communication through light signals, aiming to improve efficiency and scalability for AI data centers.

Ecovative Design LLC, established in 2007, is a biomaterials company based in Green Island, New York, with manufacturing facilities in Troy and Paradise, California. The company specializes in developing and producing sustainable materials derived from mushroom roots, known as mycelium. Ecovative's product portfolio includes Myco board, used for furniture components and work surfaces; Myco foam, employed in packaging, insulation, and acoustics; and Myco make, used in toys and other consumer goods. The company's innovative process, inspired by the natural bonding of wood chips by mycelium, aims to replace conventional plastics and foams with eco-friendly alternatives. Ecovative's products perform comparably to existing synthetics while offering a lower environmental impact. The company has received numerous awards and grants, including support from the American Society of Mechanical Engineers, the National Collegiate Inventors and Innovators Alliance, the New York State Energy Research and Development Authority, and the Environmental Protection Agency, enabling its growth and continued innovation in sustainable materials.

ID.me provides secure identity verification solutions for individuals and businesses across various sectors. It offers services such as identity proofing, authentication, multi-factor authentication, document verification, compliance monitoring, and group affiliation verification. ID.me's platform enables users to prove their identity securely online, access benefits and services, and avail discounts.

Allonnia LLC is a biotechnology company based in Boston, Massachusetts, founded in 2019, that specializes in waste remediation services. The company focuses on developing enzymes, proteins, and microbes that effectively degrade or metabolize environmental contaminants, facilitating the recovery and upcycling of valuable materials from waste. Allonnia aims to provide innovative solutions to pressing environmental challenges, including safer water and cleaner mining, while promoting sustainability. Their unique approach integrates biology with advanced technology to create systems that transform waste into useful resources. Allonnia's commitment to environmental stewardship and innovation has garnered industry recognition, positioning it as a leader in the field of biotechnology and waste management.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers across all ages, with an initial emphasis on pediatric patients. The company aims to bring effective cancer treatments to families by advancing therapies that can benefit both children and adults, prioritizing programs that can progress to the market rapidly. Day One pursues licensing or acquisition of promising products from research institutions and industry partners to expand its pipeline. Its lead candidate, DAY101, is an oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor designed to target cancers driven by the RAF signaling pathway. By applying insights from childhood cancer biology, the company seeks to address unmet needs in oncology and broaden access to precision therapies.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Color is a healthcare technology company that offers a comprehensive platform for population health management, facilitating equitable and accessible healthcare delivery. The company specializes in large-scale health initiatives, providing solutions that include population genomics programs and high-throughput testing services, such as those for COVID-19. By centralizing essential healthcare capabilities, Color enables businesses, schools, and state public health departments to implement effective preventive health programs, regardless of the geographical distribution of their populations. Its innovative approach addresses various healthcare logistics challenges, streamlining processes related to testing, screening, treatment, and referrals, while creating diverse market opportunities and revenue streams for clinical teams.

Resilient Biotics is a developer of microbiome-based therapeutics focused on addressing complex respiratory infections in both livestock animals and humans. By harnessing big data analytics and a proprietary discovery platform, the company employs high-resolution genomic analyses and machine learning algorithms to identify naturally occurring strains with immune-activating and pathogen-inhibiting capabilities. Resilient Biotics aims to create advanced screening methods and effective treatment strategies that combat deadly infectious diseases while reducing the livestock industry's reliance on antibiotics.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Edgewise Therapeutics, founded in 2017 and based in Boulder, Colorado, is a clinical-stage biopharmaceutical company dedicated to developing precision medicine therapies for severe, rare muscle disorders. The company's core expertise lies in muscle biology and small molecule engineering, which it employs through its proprietary drug discovery platform. This platform uses custom-built systems to measure integrated muscle function, enabling the identification of small molecule therapies targeting key proteins in muscle tissue. Edgewise's pipeline focuses on addressing genetically defined muscle disorders such as Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophies.

Boost Biomes, Inc. is a company that specializes in developing microbiome products for food and agriculture applications. Founded in 2016 and based in South San Francisco, California, the company utilizes a discovery platform that employs high-throughput sequencing, selective enrichment, and advanced informatics to identify multi-microbial products. This innovative approach is designed to create sustainable solutions for improving food production and extending shelf life while effectively managing diseases in high-value crops. By focusing on naturally occurring microbes, Boost Biomes aims to address challenges related to food security and enhance agricultural practices. The company's efforts represent a significant advancement over traditional methods, offering a faster and more cost-effective means of microbial product development.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Pragma Bio is a biotechnology company that uses microbiome-based approaches to discover therapies for cancer and autoimmune diseases, combining genomic sequencing, artificial intelligence, and synthetic biology to identify biomarkers and develop therapeutics through a data-driven platform that aggregates public and private data to build a microbiome database and reveal connections across microbial and clinical data. The company pursues small-molecule discovery from human-associated bacteria, focusing on the gut-immune axis, and aims to deliver health-indicative molecules with robust safety profiles, while the platform supports risk stratification and outcome prediction for patients by leveraging real-world data. Pragma Bio was founded in 2018 in Millbrae, California by Peter McCaffrey, Kovi Bessoff, Ayin Vala and Kareem Barghouti.

Conductor Tecnologia S.A. is a prominent payments processor and banking-as-a-service provider based in São Paulo, Brazil. Founded in 1997, the company specializes in credit card and electronic payment processing, along with collection and billing services for third parties. Leveraging its proprietary API-based digital processing platform, Conductor serves nearly 250 corporate clients across various industries, processing over $20 billion annually. The company manages approximately 29 million active and 80 million total end customer payment accounts, facilitating transactions at more than 2.5 million points of sale throughout Latin America. Its comprehensive suite of services empowers clients to offer efficient payment solutions to their customers.

LianBio is a biopharmaceutical company founded in 2019, headquartered in Shanghai, China, with an additional office in Princeton, New Jersey. The company is dedicated to the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as addressing other unmet medical needs in Greater China and major Asian markets. LianBio focuses on in-licensing assets and collaborates with leading partners to enhance its pipeline, which includes clinically validated product candidates across various therapeutic areas such as cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory indications. The company aims to accelerate the availability of innovative medicines to improve patient outcomes through a science-driven approach.